| 1 |
35351776 | Reevaluate In Vitro CYP3A Index Reactions of Benzodiazepines and Steroids between Humans and Dogs. | 2022 Jun |
1 |
| 2 |
32112986 | Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. | 2020 May 20 |
6 |
| 3 |
29848078 | Influence of ethanol on the metabolism of alprazolam. | 2018 Jun |
8 |
| 4 |
26315684 | Evaluation of Cytochrome P450 (CYP) 3A4-Based Interactions of Levomilnacipran with Ketoconazole, Carbamazepine or Alprazolam in Healthy Subjects. | 2015 Oct |
2 |
| 5 |
22159869 | Metabolism of alprazolam (a marker of CYP3A4) in hemodialysis patients with persistent inflammation. | 2012 May |
6 |
| 6 |
20080160 | Benzodiazepines medazepam and midazolam are activators of pregnane X receptor and weak inducers of CYP3A4: investigation in primary cultures of human hepatocytes and hepatocarcinoma cell lines. | 2010 Mar 15 |
1 |
| 7 |
20501911 | Metabolite formation kinetics and intrinsic clearance of phenacetin, tolbutamide, alprazolam, and midazolam in adenoviral cytochrome P450-transfected HepG2 cells and comparison with hepatocytes and in vivo. | 2010 Sep |
1 |
| 8 |
17200836 | Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. | 2007 Feb |
3 |
| 9 |
17639026 | Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. | 2007 Oct |
1 |
| 10 |
17979656 | Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. | 2007 Oct |
1 |
| 11 |
16791582 | Effect of tofisopam on the single-oral-dose pharmacokinetics and pharmacodynamics of the cyp3a4 probe drug alprazolam. | 2006 Jul |
1 |
| 12 |
15806426 | Alprazolam as a probe for CYP3A using a single blood sample: pharmacokinetics of parent drug, and of alpha- and 4-hydroxy metabolites in healthy subjects. | 2005 Apr |
2 |
| 13 |
15903124 | Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. | 2005 Apr |
1 |
| 14 |
14709940 | Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. | 2004 Feb |
1 |
| 15 |
15342470 | Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. | 2004 Dec |
1 |
| 16 |
12920410 | Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine. | 2003 Aug |
1 |
| 17 |
13129991 | Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. | 2003 Sep 17 |
2 |
| 18 |
14586385 | Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics. | 2003 Nov |
1 |
| 19 |
24930414 | Symptomatic hypotension with venlafaxine-benzodiazepine interaction. | 2003 |
1 |
| 20 |
11304902 | Effect of alosetron on the pharmacokinetics of alprazolam. | 2001 Apr |
1 |
| 21 |
11549205 | No correlations between the urinary ratio of 6beta-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam. | 2001 Jul |
1 |
| 22 |
11745908 | In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. | 2001 Mar |
2 |
| 23 |
10664927 | Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A4 promoter region. | 2000 Feb |
1 |
| 24 |
10688619 | Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes. | 2000 Mar |
1 |
| 25 |
10770452 | Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. | 2000 Apr |
1 |
| 26 |
10801241 | Alprazolam-ritonavir interaction: implications for product labeling. | 2000 Apr |
1 |
| 27 |
10548453 | Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. | 1999 Sep |
5 |
| 28 |
10634135 | Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. | 1999 Dec |
3 |
| 29 |
9498726 | Lack of multiple dosing effect of sertindole on the pharmacokinetics of alprazolam in healthy volunteers. | 1998 Feb |
2 |
| 30 |
9536449 | Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. | 1998 May |
2 |
| 31 |
9641003 | Effect of venlafaxine on the pharmacokinetics of alprazolam. | 1998 |
1 |
| 32 |
9784084 | Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. | 1998 Oct |
3 |
| 33 |
9098872 | Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. | 1997 Mar |
3 |
| 34 |
8610817 | Newer antidepressants and the cytochrome P450 system. | 1996 Mar |
1 |
| 35 |
8646822 | A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. | 1996 May |
4 |
| 36 |
8905799 | [The relationship between single-oral dose kinetics of alprazolam and cytochrome P4503A and cytochrome P4502C19]. | 1996 Jun |
4 |
| 37 |
8968657 | Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. | 1996 Dec |
1 |
| 38 |
8748428 | Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. | 1995 Dec |
2 |
| 39 |
8748566 | Nefazodone: a new antidepressant. | 1995 Dec 15 |
1 |